NCT04302415

Metabolomics Explores Biomarkers for Metastatic Breast Cancer

Clinical Study of Metabolomics-based Approach Explore Biomarkers for Metastatic Breast Cancer

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Shandong Cancer Hospital and Institute · Academic / Other
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

RATIONALE: Studying samples of plasm by metabolomics-based approach from women with metastasis breast cancer may help doctors understand the biomarker of visceral metastasis. PURPOSE: This clinical trial is studying the biomarker of visceral metastasis by metabolomics approach in metastasis breast cancer undergoing treatment.

Detailed description

Imaging evaluation of the effect of chemotherapy on patients with visceral metastases from breast cancer, metabolomics was used to analyze the changes of metabolites in plasma, and to find biomarkers that could reflect visceral metastasis and treatment effects. The purpose is to help clinicians predict whether patients have potential visceral metastases, evaluate the effects of visceral metastasis treatment, and reflect the patient's prognosis. Patients with visceral metastases on imaging examinations received chemotherapy as planned, and blood samples were collected from patients before and during imaging assessments. Analysis of metabolites in plasma using ultra high performance liquid chromatography. Patient information were collected through medical record, including race, age, height and body mass index, menarche age, menstrual status, menopausal age (if applicable), tobacco and alcohol history, motherhood history, family history, etc.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	There is no other intervention, only clinical treatment.	There is no other intervention, only clinical treatment.

Timeline

• Start date: 2019-10-01
• Primary completion: 2020-03-01
• Completion: 2023-02-01
• First posted: 2020-03-10
• Last updated: 2020-03-10

Locations

1 site across 1 country: China